Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A B-cell lymphoma that is characterized by the abnormal rearrangement of two genes, MYC gene and either BCL2 or BCL6 genes.
No clinical trials have been registered for high-grade B-cell lymphoma double-hit/triple-hit.
6 publications have been identified in PubMed for high-grade B-cell lymphoma double-hit/triple-hit. Research spans Clinical Trial Publication (33%), Epidemiology / Natural History (33%), and Review / Meta-Analysis (17%).
Miyaoka M (2026). [PMID: 41883013](https://pubmed.ncbi.nlm.nih.gov/41883013/). *Histopathology*. [Epidemiology / Natural History]
Cancio JEG (2025). [PMID: 40438479](https://pubmed.ncbi.nlm.nih.gov/40438479/). *Acta medica Philippina*. [Epidemiology / Natural History]
Dodero A (2025). [PMID: 40763273](https://pubmed.ncbi.nlm.nih.gov/40763273/). *Blood advances*. [Clinical Trial Publication]
Zhao Y (2024). [PMID: 39075995](https://pubmed.ncbi.nlm.nih.gov/39075995/). *Zhonghua yi xue za zhi*. [Clinical Trial Publication]
Zanelli M (2024). [PMID: 39684922](https://pubmed.ncbi.nlm.nih.gov/39684922/). *International journal of molecular sciences*. [Review / Meta-Analysis]
Data assembled from 2 of 12 sources · Last updated Sep 20, 2026, 1:01 AM UTC
De Jonge AV (2024). [PMID: 38961740](https://pubmed.ncbi.nlm.nih.gov/38961740/). *Haematologica*. [Basic Science / Preclinical]
AI-curated news mentioning high-grade B-cell lymphoma double-hit/triple-hit
Updated Mar 16, 2026
A recent study highlights a rare association between high-grade follicular B-cell lymphoma and C3 rapidly progressive glomerulonephritis. This discovery may provide insights into the complex interplay between these conditions.